Evaluating Country Performance After Transitioning From Gavi Assistance: An Applied Synthetic Control Analysis.


Journal

Global health, science and practice
ISSN: 2169-575X
Titre abrégé: Glob Health Sci Pract
Pays: United States
ID NLM: 101624414

Informations de publication

Date de publication:
28 08 2023
Historique:
received: 07 03 2023
accepted: 28 07 2023
medline: 31 8 2023
pubmed: 29 8 2023
entrez: 28 8 2023
Statut: epublish

Résumé

Over the past decade, international development assistance for health has slowed. As donors seek to increase domestic cofinancing and ultimately transition countries from donor aid dependence, COVID-19 has severely constrained public budgets. The evaluation of sustainability and longer-term impacts of donor withdrawal is increasingly important. We assess vaccination coverage and post-neonatal mortality to estimate country performance of these outcomes among countries that no longer received assistance from Gavi, the Vaccine Alliance (Gavi) between 2000 and 2018. Using data from all countries receiving Gavi support between 2000 and 2020, we employed a synthetic control method to generate a pre-transition counterfactual with the same characteristics as the observation of interest to predict a future that empirically never existed. The synthetic unit is constructed from the weighted average of other units with good fit to the unit of interest before transition but did not transition. We found substantial heterogeneity after transitioning from Gavi assistance. China, Guyana, and Turkmenistan overperformed their expected coverage rates; Albania, Bhutan, China, Guyana, and Turkmenistan maintained coverage over 90%; and Bosnia and Herzegovina and Ukraine reported precipitous drop-offs that fell well below their synthetic controls. We also observed a vaccination coverage decline in 2020 for several countries after transitioning and most synthetic controls, which we attribute to COVID-19-related service disruptions. We recommend that Gavi adjust its transition model to systematically assess contextual externalities and risk. In addition, countries that no longer receive Gavi assistance can leverage technical assistance and communities of practice to mutually assist each other and other countries advancing toward transition. This could also foster intracountry accountability after transition. We also recommend that Gavi systematize post-transition assessments and evaluations that leverage the expertise and experience of graduated countries to encourage cross-learning.

Identifiants

pubmed: 37640489
pii: GHSP-D-22-00536
doi: 10.9745/GHSP-D-22-00536
pmc: PMC10461703
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Kolesar et al.

Références

Health Policy Plan. 2015 Mar;30(2):197-205
pubmed: 24510369
Lancet. 2011 Jan 1;377(9759):85-95
pubmed: 20619886
Lancet. 2018 Oct 27;392(10157):1513-1514
pubmed: 30316457
J Immunol Sci. 2018 Aug 2;Suppl(13):89-93
pubmed: 30882091
Glob Public Health. 2014;9(8):865-79
pubmed: 25156323
Health Aff (Millwood). 2016 Feb;35(2):199-207
pubmed: 26858370
Vaccine. 2020 Jan 16;38(3):588-596
pubmed: 31679863
Lancet Glob Health. 2016 Sep;4(9):e627-32
pubmed: 27492820
Allergy Asthma Proc. 2021 Sep 1;42(5):378-385
pubmed: 34474707
Public Health. 2017 Dec;153:163-171
pubmed: 29102832
Pediatr Infect Dis J. 2018 May;37(5):407-412
pubmed: 29278610
Health Aff (Millwood). 2016 Feb;35(2):250-8
pubmed: 26858377
Vaccine. 2023 Jan 11;:
pubmed: 36639274
J Epidemiol Community Health. 2018 Aug;72(8):673-678
pubmed: 29653993
J Glob Health. 2018 Jun;8(1):010301
pubmed: 29391944
Lancet. 2009 Jan 17;373(9659):209
pubmed: 19108881
Glob Health Sci Pract. 2019 Jun 27;7(2):258-272
pubmed: 31249022
BMC Public Health. 2021 Jan 19;21(1):160
pubmed: 33468094
BMJ. 2020 Oct 23;371:m4040
pubmed: 33097492
Arch Dis Child. 2015 Feb;100 Suppl 1:S34-7
pubmed: 25613965
BMJ Glob Health. 2019 Dec 03;4(6):e001789
pubmed: 31908857
Asia Pac J Public Health. 2019 Sep;31(6):485-498
pubmed: 31462059
Global Health. 2021 Aug 26;17(1):95
pubmed: 34446050
Glob Public Health. 2010;5(2):129-35
pubmed: 20213563
Vaccine. 2018 Oct 29;36(45):6858-6866
pubmed: 30268735
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1495-1500
pubmed: 34710074
Vaccine. 2020 Feb 18;38(8):1906-1914
pubmed: 31980190
Health Econ. 2016 Dec;25(12):1514-1528
pubmed: 26443693
Popul Health Metr. 2022 Jan 6;20(1):2
pubmed: 34986844
Glob Health Sci Pract. 2015 Dec 17;3(4):591-605
pubmed: 26681706

Auteurs

Robert John Kolesar (RJ)

Palladium, Washington, DC, USA.
Centre d'Études et de Recherche sur le Développement International, Université Clermont Auvergne, Clermont-Ferrand, France.

Rok Spruk (R)

School of Economics and Business, University of Ljubljana, Ljubljana, Slovenia.

Tsheten Tsheten (T)

Royal Centre for Disease Control, Ministry of Health, Thimphu, Bhutan.
National Centre for Epidemiology and Population Health, College of Health and Medicine, Australian National University, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH